FDA green lights early access to pancreatic cancer drug, daraxonrasib

The FDA said it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug ...

For pancreatic cancer, the FDA grants early access to the experimental drug daraxonrasib

Pancreatic cancer is one of the deadliest cancers. It’s estimated that more than 52,000 people will die from it this year, ...

Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy

Erasca (ERAS), a potential rival to Revolution Medicines (RVMD) in developing drugs targeting cancer-causing mutations in the ...

F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer

Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.
Hosted on MSN

BeOne Medicines advances early cancer trial for BG-75098, signaling steady pipeline progress

BeOne Medicines (ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early-stage trial to test a new cancer drug, BG-75098, in adults with advanced solid tumors.

Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test

A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of ...